B. Riley raised the firm’s price target on Zymeworks (ZYME) to $40 from $30 and keeps a Buy rating on the shares. Zymeworks’ shift to a royalty-aggregation strategy aims to optimize future de-risked cash flows from partnered programs and the potential partnering of ZW191 in 2026, the analyst tells investors in a research note. By retaining in-house R&D, acquiring royalties rather than assets, and diversifying therapeutic exposure, the company reduces binary risk while maintaining scientific rigor, with a strengthened leadership team enhancing prospects for attractive, risk-adjusted shareholder returns, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $40 from $37 at Leerink
- Zymeworks price target raised to $25 from $17 at Wells Fargo
- Zymeworks price target raised to $40 from $30 at Stifel
- Zymeworks’ Promising Phase 3 Results Drive Buy Rating for HER2-Positive Cancer Treatment
- Zymeworks Appoints Scott Platshon as Acting CIO